Results 251 to 260 of about 278,336 (309)

T-cell redirecting therapies in lung cancer - a comprehensive analysis of clinical trials. [PDF]

Front Immunol
Zhao J, Bangolo A, Zhang L, Gutierrez M, Gonzalez-Velez M.   +4 more
europepmc   +1 more source

Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer. [PDF]

J Immunother Cancer
Fernández-Luna C, Baena J, Calles A, Antoñanzas-Basa M, Lage Alfranca Y, Mielgo X, Sereno M, Cervera R, Cabezon-Gutierrez L, López A, Rubio J, Conde E, Lopez-Rios F, Alvarez-Vallina L, Valencia K, Montuenga LM, Ruiz De Garibay G, Molero M, Adradas V, Curto-Aguilera D, Peressini M, Carrera-Elvira E, Ballesteros D, Portillo-Fernández A, Lopez-Cárdenas T, Serrano-Gómez C, Bote H, Torres-Jiménez J, Cruz-Bermúdez A, Provencio M, Paz-Ares L, Sánchez-Herrero E, Zugazagoitia J.   +32 more
europepmc   +1 more source

Session for NSCLC

The Japanese journal of thoracic diseases, 1994
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

NSCLC

Onkologische Welt, 2023
Nach Daten der Studie FLAURA2 zeigt Osimertinib plus Chemotherapie in der Behandlung des nicht-kleinzelligen Lungenkarzinoms (NSCLC) einen statistisch signifikanten Vorteil beim progressionsfreien Überleben (PFS) im Vergleich zu Osimertinib allein. Studienleiter Dr. Pasi Jänne, Boston (USA), stellte die Ergebnisse der Studie vor.
openaire   +1 more source

Cemiplimab (Libtayo) for NSCLC

The Medical Letter on Drugs and Therapeutics, 2023
The FDA has approved cemiplimab-rwlc (Libtayo – Regeneron), an immune checkpoint inhibitor, for use in combination with platinum-based chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1 aberrations
openaire   +2 more sources

Capmatinib (Tabrecta) for NSCLC

The Medical Letter on Drugs and Therapeutics, 2023
The FDA has granted regular approval to the oral kinase inhibitor capmatinib (Tabrecta – Novartis) for treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. MET exon 14 skipping mutations occur in 3-4% of NSCLC cases.
openaire   +2 more sources

Assessing Toripalimab in NSCLC

Cancer Discovery, 2022
Abstract According to CHOICE-01, a phase III trial in China, the PD-1 inhibitor toripalimab plus chemotherapy improves progression-free survival in patients with untreated non–small cell lung cancer lacking actionable mutations. The findings boost combination chemo–immunotherapy, rather than chemotherapy alone, as the new standard for ...
openaire   +2 more sources

Prognosis in N2 NSCLC

Lung Cancer, 2004
The prognosis of bronchogenic carcinoma in stage III N2 is poor. Five-year survival ranges between 0 and 5%. Lymph-node involvement itself still is the main prognostic factor. Complete lymphadenectomy improves long-term survival in contrast to lymph-node sampling.
Godehard, Friedel, Volker, Steger, Thomas, Kyriss, Jutta, Zoller, Heikki, Toomes   +4 more
openaire   +2 more sources

A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care

Journal of Oncology Pharmacy Practice, 2020
Lung cancer is a complex, genetically heterogeneous disease. It is the most common cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) represents the majority of the diagnosed lung cancer cases. Osimertinib is a new treatment option that demonstrated a superior efficacy over standard epidermal growth factor receptor tyrosine ...
Osama M Al-Quteimat, Amer M Amer
openaire   +2 more sources